| NCT ID | NCT07147179 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Central Nervous System Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-04-02 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2026-04-02 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single arm prospective pilot trial determining the safety of short-course radiation therapy in pediatric patients with incurable central nervous system malignancies.
Eligibility Criteria
Inclusion Criteria: * Male or female, aged 21 years or below * Lansky performance status \>= 40 * Has a diagnosis of an incurable malignancy that: * Originates outside the brain but is metastatic to 1 or more sites within the brain, or originates and recurs within the brain. For this diagnosis to be confirmed, there must be multidisciplinary review of up to date imaging at a pediatric tumor board with unanimous consensus of intracranial relapse or metastasis. If the consensus is not unanimous, short-interval repeat imaging with subsequent unanimous consensus would be required in order for this eligibility criteria to be met * Has at least 1 targetable intracranial lesion as seen on imaging * Has a multidisciplinary consensus recommendation for palliative intent radiation * Consents to the study or has caregiver who is able to provide signed and dated informed consent. For subjects under the age of 18, a signed and dated assent form as able. * Patients who had prior radiation in planned treatment area are also eligible to enter the trial * Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: * Radiotherapy for curative intent * Serious uncontrolled systemic or psychiatric disorders that would interfere with participation in the protocol * Being planned for proton radiation
Contact & Investigator
Michael LaRiviere, MD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT07147179 clinical trial?
This trial is open to participants of all sexes, up to 21 Years, studying Central Nervous System Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07147179 currently recruiting?
Yes, NCT07147179 is actively recruiting participants. Contact the research team at Kelly.Clark3@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07147179 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07147179 clinical trial?
NCT07147179 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Michael LaRiviere, MD at University of Pennsylvania. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.